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AbstrAct
Objective Studies have suggested a shared genetic 
aetiology between congenital long QT syndrome (LQTS) 
and diabetes, epilepsy and mental disorders. We 
investigated the prevalence of metabolic, neurological and 
psychiatric comorbidities in LQTS patients.
Methods This retrospective cohort study was based on 
data from nationwide Danish registries, 2003–2017. LQTS 
patients were matched 1:5 with controls on sex and age.
Results We matched 463 LQTS patients with 2315 
controls from the background population. Mean age 
was 35.7 (SD 21.0) years, and 38% were males in both 
groups. LQTS patients had a higher prevalence of atrial 
fibrillation (6.5% vs 2.3%, p<0.001), diabetes (3.7% vs 1.8 
%, p=0.011) and hearing loss (3.2% vs 1.7%, p=0.027). 
LQTS patients had a higher prevalence of psychiatric 
disorders overall (13.0% vs 9.1%, p=0.01) but the 
difference could not be attributed to a specific psychiatric 
disease subgroup. LQTS patients had a higher prevalence 
of neurological disorders (22.0% vs 13.2%, p<0.001), 
largely driven by epilepsy (6.7% vs 1.6%, p<0.001). In 
20/27 (74%) of the LQTS patients, the epilepsy diagnosis 
did not reappear in the registries after the LQTS diagnosis 
was established.
Conclusions In this nationwide cohort, patients with 
LQTS had a significantly increased burden of diabetes, 
neurological and psychiatric comorbidities, compared 
with the background population. The higher prevalence of 
neurological comorbidities was largely driven by epilepsy, 
despite a high rate of potentially misdiagnosed patients 
prior to LQTS diagnosis. Our data support that LQTS may 
be considered a multiorgan disease and suggest that 
patient management should be adjusted accordingly.
IntROduCtIOn
The congenital long QT syndrome (LQTS) 
is a rare inherited cardiac disease that may 
result in syncope and malignant arrhythmias. 
In approximately 75% of the LQTS patients, 
a disease-causing mutation can be identified 
in one of the three LQTS genes (KCNQ1, 
KCNH2 and SCN5A) coding for ion channels 
involved in the cardiac repolarisation.1
The initial LQTS cases described comprised 
cases of the Jervell-Lange-Nielsen syndrome, 
a rare KCNQ1 and KCNE1 associated LQTS 
subtype that causes congenital deafness, 
arrhythmia susceptibility, and sudden cardiac 
death.2 It has since become well known that 
mutations in the LQTS-associated genes can 
present with various cardiac phenotypes such 
as the Brugada syndrome, early onset of atrial 
fibrillation and cardiomyopathies.3 4 In addi-
tion, more extracardiac manifestations have 
become evident during recent years. Epilepsy 
and sudden unexpected death in epilepsy 
have in several cases been linked to KCNH2, 
and SCN5A mutations5–9 and an exploratory 
Key questions
What is already known about this subject?
 ► Small experimental and genetic studies have linked 
long QT syndrome (LQTS) with several extracardiac 
manifestations such as diabetes, epilepsy and psy-
chiatric disorders, but this has not been tested in a 
real-life cohort.
What does this study add?
 ► In our nationwide data, patients with LQTS had a sig-
nificantly increased burden of diabetes, neurological 
and psychiatric comorbidities compared with an age 
and gender-matched background population.
How might this impact on clinical practice?
 ► Our data support that LQTS may be considered a 
multiorgan disease and suggest that patient care 
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study found an increased epileptiform activity, primarily 
in LQTS patients with KCNH2 mutations.10 Mutations in 
the KCNH2 gene have also been associated with cerebral 
or mental disorders such as schizophrenia and impaired 
cognition.11 12 As a result, the concept of ‘cardiocerebral 
channelopathies’ has emerged.13
Similarly, studies have suggested a link between the 
LQTS causing genes and risks of metabolic disturbances. 
LQTS patients with KCNQ1 or KCNH2 mutations display 
an increased insulin release following glucose intake 
resulting in a clinically relevant increased risk of hypo-
glycaemia.14 15
Currently, it is undetermined whether such extracar-
diac manifestations are more frequently diagnosed in a 
real-world population of LQTS patients. This nationwide 
study investigated the burden of metabolic, psychiatric 
and neurological comorbidities in a Danish cohort of 
patients with LQTS, compared with the disease burden 
in the general population.
MetHOds
study design and registries
This study was a retrospective, nationwide cohort study 
based on data from nationwide Danish registries, 
including the Danish National Prescription Registry, the 
National Population Register, and the Danish National 
Patient Register. By use of the unique social security 
number, given to all citizens on birth or immigration, we 
were able to link data from several registries at the indi-
vidual level. Denmark has a freely available, tax-financed, 
public healthcare system for all citizens irrespective of 
income and social class. Only two per cent of health-
care activities are managed in private hospitals, and the 
demands for reporting to the central registries are the 
same as in the public hospital setting. Data on in-hospital 
diagnosis and procedures are consistently reported to the 
Danish National Patient Register on hospital discharge 
and following consultations in the outpatient clinic. This 
setup ensures a complete record of registered health-
care activities. Date of death is continuously reported 
to the National Population Register ensuring complete 
follow-up on vital status. All prescriptions dispensed from 
Danish pharmacies are collected in the Danish National 
Prescription Registry due to partial government reim-
bursement, which has been shown to accurately reflect 
patient’s history of filled prescriptions. The registries 
have been described in further detail elsewhere.16–18
Records were deidentified by central authorities prior 
to our analysis; names and addresses were removed, and 
social security numbers were encrypted. Efforts were 
made not to report data that may aid in the identification 
of individuals. Hence, Danish law prohibits reporting 
of low group numbers (n<3), which were replaced with 
‘na’ throughout the paper or omitted entirely. The exact 
numbers are known to the investigators. Our study period 
went from 2003 until June 2017.
Identification of LQts population and matched controls
We identified all patients diagnosed for the first time with 
congenital LQTS based on the WHO International Clas-
sification of Disease, 10th edition (ICD-10) DI472E code 
received in hospital or in an outpatient clinic. Patients 
were characterised and followed from the date of first 
diagnosis, henceforth referred to as index. If patients 
with congenital LQTS at index later received a diagnosis 
of acquired LQTS (DI472F), the patients were excluded 
from the analyses. Each LQTS patient was matched with 
five controls, forming the control group.
Validation of the LQts diagnosis in danish registries
To investigate the accuracy of the congenital LQTS ICD-10 
code, we manually reviewed all charts of patients receiving 
a diagnosis of congenital LQTS (DI472E) at Rigshospi-
talet, Copenhagen, Denmark between November 2016 
and March 2019. During this period, 123 patients with a 
DI472E diagnosis code were identified. After the manual 
review, we were able to verify the diagnosis in 120 out of 
123 patients (positive predictive value=97.6%).
Comorbidities
Comorbidities were defined based on hospital discharge 
diagnoses, including both in-hospital admissions and 
hospital outpatient clinic visits, coded according to the 
ICD-10 at any time before and after index.
Cardiovascular comorbidities in focus were acute 
myocardial infarction (I20, I23-I25), venous thrombo-
embolism (I26, I82, I80, excluding I820, I800 and I808), 
peripheral vascular disease (I70, I74), and atrial fibrilla-
tion (I48).
Metabolic comorbidities in focus were diabetes mellitus 
with complications (E10-E14, excluding E109, E119, 
E129, E139), hypoglycaemia (E100E, E110B, E159, E159, 
E161, E162) and hypothyroidism (E03). To strengthen 
the diabetes diagnosis, claimed prescription on antidi-
abetic drugs and insulin were analysed separately as a 
proxy for diabetes.
We defined a variable covering any neurological 
diseases (G00-G99) and further stratification based on 
major ICD-10 subgroups; inflammatory diseases of the 
central nervous system (G00-G09), systemic atrophies 
primarily affecting the central nervous system (G10-14), 
extrapyramidal and movement disorders (G20-26), other 
degenerative disease and demyelinating diseases (G30-
G37), episodic and paroxysmal disorders (G40-47), nerve 
and plexus disorders (G50-59), polyneuropathies (G60-
64), disease of myoneural junction and muscle (G70-73), 
cerebral palsy (G80-83), other disorders of the nervous 
system (G90-99). In addition, a variable covering hearing 
loss (H912, H918, H932, H933) was added and for prac-
tical reasons listed under neurological disorders.
The epilepsy diagnosis (G40-41) was singled out for 
further analysis. First, to address the possibility that 
epilepsy might be misdiagnosed as LQTS and vice 
versa due to similar symptomatic traits, we stratified all 
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to the index date. Four groups were defined including 
all patients receiving an epilepsy diagnosis prior to index 
(preindex), patients where the initial diagnosis did not 
reappear following index (dismissed), patients with 
a diagnosis following index without a diagnosis prior 
to index (acquired), and a summary group of patients 
with an epilepsy diagnosis anytime following index 
(postindex). It is noted that the groups are not mutu-
ally exclusive (see table 2 for a flow chart illustration). 
Second, we conducted separate analysis defining epilepsy 
based on antiepileptic drug use.
We defined a variable covering any psychiatric disorder 
(F00-99) and further stratifications based on major 
ICD-10 subgroups that is, organic mental disorders (F00-
09), mental disorders due to substance use (F10-19), 
schizophrenia (F20-29), affective disorders (F30-39), 
neurotic and somatoform disorders (F40-48), behavioural 
syndromes (F50-59), personality disorders (F60-69), 
mental retardation (F70-79), disorders of psychological 
development (F80-89) and behavioural disorders with 
onset in childhood (F90-98).
statistics
LQTS patients were matched using a greedy match 
macro for SAS V.9.4, matching patients (1:5) on sex and 
birth year allowing for zero variation. Finally, we made 
sure that no controls died prior to the assigned index 
date of their respective LQTS case, to exclude any risk 
of immortality. Differences in patient characteristics were 
compared using Fishers exact test for continuous varia-
bles, and χ2 test for categorical variables. Follow-up time 
was compared as medians with IQR and a p value was esti-
mated using the non-parametric Wilcoxon signed-rank 
test. ORs with 95% CIs were estimated using conditional 
logistic regression models.
Forest plot illustration was made using R V.3.4.1 (Single 
Candle). Data management and analyses were performed 
SAS V.9.4. Two-sided p values <0.05 were considered 
statistically significant.
ResuLts
We identified 474 patients with a first time LQTS diag-
nosis. Subsequently, 11 patients were reclassified as 
acquired LQTS and excluded. The remaining 463 
patients were matched with 2315 controls from the 
background population. Following successful matching, 
mean age ±SD was 35.7±21.0 years (LQTS; 35.6±20.9 
years and controls; 35.8±21.0 years, p=0.84) and 38.0% 
were males in both groups (table 1). The follow-up time 
did not differ between groups (LQTS; median 4.4 years, 
IQR 2.2–7.8 years vs controls; 4.3 years, IQR 2.1–7.6 years, 
p=0.44). Also, the all-cause mortality was similar in the 
LQTS patients compared with controls during follow-up 
(4.2% vs 3.6%, respectively, p=0.49).
Cardiovascular comorbidities
Compared with controls, LQTS patients had a signifi-
cantly higher prevalence of atrial fibrillation (6.5% vs 
2.3%, p<0.001) and acute myocardial infarction (3.0% vs 
1.5%, p=0.019) (see figure 1). No difference was found 
comparing the prevalence of venous thromboembolism 
(2.2% vs 1.8%, p=0.57) and peripheral vascular disease 
(0.9% vs 0.6%, p=0.45).
neurological comorbidities
LQTS patients had an overall higher prevalence of 
neurological disorders (22.0% vs 12.3%, p<0.001), driven 
by an increased risk of episodic and paroxysmal disorders 
(13.6% vs 6.3%, p<0.001) and nerve and plexus disorders 
(6.5% vs 4.2%, p=0.031). No difference was observed for 
polyneuropathies (1.5% vs 1.1%, p=0.48), myoneural 
junction disorders (0.6% vs 0.2%, p=0.11) and cerebral 
palsy (0.6% vs 0.2%, p=0.26). LQTS patients had signifi-
cantly more hearing loss (3.2% vs 1.7%, p=0.027).
The epilepsy diagnosis, a subset of the episodic and 
paroxysmal disorders diagnosis group, was more preva-
lent among LQTS patients anytime according to index 
(6.7% vs 1.6%, p<0.001) as well as preindex (5.8% vs 
1.0%, p<0.001) and postindex (2.4% vs 0.6%, p<0.001) 
(table 2). LQTS patients more often received an epilepsy 
diagnosis that was dismissed after index (4.3% vs 1.0%, 
p<0.001), which was the case in 20 of 27 LQTS patients 
(74%) diagnosed with epilepsy prior to index of the 
initially diagnosed LQTS patients. None of the 20 patients 
with a dismissed epilepsy diagnosis filled a prescription 
on antiepileptic drugs postindex.
In a separate sensitivity analysis, defining epilepsy only 
based on antiepileptic drug use, we also found epilepsy 
to be more prevalent among LQTS patients overall (4.3% 
vs 1.0%, p<0.001), which was also found both preindex 
(3.7% vs 0.9%, p>0.001) and postindex (3.7% vs 0.9%, 
p>0.001).
Psychiatric comorbidities
LQTS patients had a higher prevalence of psychiatric 
diseases overall (13.0% vs 9.1%, p=0.010). We observed 
a trend towards higher prevalence for two of the psychi-
atric disease subgroups among LQTS patients compared 
with controls, although none of them reached statistical 
significance; organic mental disorders (4.8% vs 3.2%, 
p=0.084), mental disorders due to substance use (6.3% 
vs 4.2%, p=0.056), affective disorders (1.9% vs 1.7%, 
p=0.75) and anxiety (3.0% vs 2.2%, p=0.26).
Metabolic comorbidities
LQTS patients were more often diagnosed with diabetes 
mellitus (3.7% vs 1.8% p=0.011), with no difference for 
hypothyroidism (1.1% vs 1.4%, p=0.60) (table 1). Hypo-
glycaemia was present in less than three LQTS patients, 
and data were censored.
LQTS patients were also more often prescribed antidi-
abetic medication overall (5.2% vs 1.9%, p<0.001) and 
insulin (1.9% vs 0.6%, p=0.006) (table 3). Prior to index, 
the increased risk of diabetes (based on in-hospital diag-
nostic codes) was not statistically significantly higher in 
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Table 1 Characteristics and comorbidities for patients with long QT syndrome (LQTS) and their matched controls
Demographics
LQTS (463) Controls (2315)
P valueN % N %
Age at diagnosis mean, (SD) 35.6 (±20.9) 35.8 (±21.0) 0.836
Sex, male 176 38.0 880 38.0 1.000
Cardiovascular comorbidities
  Atrial fibrillation 30 6.5 53 2.3 <0.001
  Venous thromboembolism 10 2.2 41 1.8 0.569
  Peripheral vascular disease 4 0.9 13 0.6 0.446
  Acute myocardial infarction 14 3.0 34 1.5 0.019
Metabolic comorbidities
  Diabetes mellitus 17 3.7 42 1.8 0.011
  Hypothyroidism 5 1.1 32 1.6 0.604
Neurological comorbidities
  Any neurological disease 102 22.0 285 12.3 <0.001
  Episodic and paroxysmal disorders 63 13.6 145 6.3 <0.001
  Nerve and plexus disorders 30 6.5 97 4.2 0.031
  Polyneuropathies 7 1.5 26 1.1 0.481
  Myoneural junction 3 0.6 5 0.2 0.113
  Cerebral palsy 3 0.6 7 0.3 0.257
  Hearing loss 15 3.2 39 1.7 0.027
Psychiatric comorbidities
  Any psychiatric disorder 60 13.0 210 9.1 0.010
  Organic mental disorders 22 4.8 73 3.2 0.084
  Mental disorders due to substance use 29 6.3 98 4.2 0.056
  Affective disorders 9 1.9 40 1.7 0.747
  Neurotic and somatoform disorders 14 3.0 50 2.2 0.258
p=0.10), whereas LQTS patients more often filled 
prescription for antidiabetic medication (4.5% vs 1.7%, 
p<0.001) and insulin (1.7% vs 0.6%, p=0.008). In 21/24 
(87.5%) of the LQTS patients, the antidiabetic treatment 
was prescribed prior to index (table 3).
dIsCussIOn
In this study, we included a nationwide cohort of patients 
with congenital LQTS, matched with relevant controls 
from the background population. Analysing the risks of 
extracardiac disorders, we found that LQTS patients had 
a significantly increased burden of diabetes, psychiatric 
and neurological comorbidities, in addition to the well-
known risks of cardiac comorbidities. The risk of epilepsy 
seemed especially pronounced, even after taking into 
account the potentially misdiagnosed cases of epilepsy. 
Findings of this study support the multimorbid nature of 
LQTS and may be of importance for clinicians in order 
to manage both cardiac and extracardiac comorbidities 
from an early stage.
Cardiovascular comorbidities
Findings from this study confirms the well-known 
increased risk of atrial fibrillation in LQTS patients,4 
but our data also show an increased risk of myocardial 
infarctions in the LQTS patients. An important caveat in 
interpreting these results is that LQTS patients will be 
offered regular visits at the cardiology department, intro-
ducing a potential bias towards higher cardiac disease 
prevalence among LQTS patients, when compared with 
the background population. Still, then one would also 
expect peripheral vascular disease and thromboembolic 
to be more prevalent, but they were not. The causal 
explanation for an increased risk of myocardial infarc-
tion remains uncertain but it may be hypothesised that 
the increased prevalence of diabetes among patients with 
LQTS may contribute to an increased risk of myocardial 
infarction. However, as the mean age of these patients is 
low and diabetes overall infrequent, the question remains 
open for further investigation.
neurological comorbidities
Our finding that LQTS patients have an increased risk of 
neurological disorders, especially epilepsy, is important, 
as several research groups have previously indicated that 
epilepsy may share a molecular background with LQTS. 
A study by Auerbach et al demonstrated an increased risk 
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Figure 1 Comparison of comorbidities between long QT syndrome (LQTS) patients and their age and gender matched 
controls (1:5). Forrest plot depicts conditional logistic regression with ORs and 95% CIs. Background population is used 
as reference, and an OR exceeding 1 represents an increased risk of the investigated comorbidity for LQTS patients. In the 
subanalysis, epilepsy is compared in relation to time of LQTS diagnosis (index). *Composite of the ICD-10 codes H912, H918, 
H932 H933 and not included in the any neurological disorders category. **Epilepsy included in episodic disorders.




LQTS patients with epilepsyN % N %
Anytime; Epilepsy 31 6.7 37 1.6 <0.001
  
Anytime; Antiepileptics 20 4.3 23 1.0 <0.001
Preindex; Epilepsy 27 5.8 24 1.0 <0.001
Preindex; Antiepileptics 17 3.7 21 0.9 <0.001
Dismissed†; Epilepsy 20 4.3 23 1.0 <0.001
Dismissed; Antiepileptics 4 0.9 7 0.3 0.079
Acquired*; Epilepsy 4 0.9 13 0.6 0.446
Acquired; Antiepileptics 3 0.6 3 0.1 0.028
Postindex; Epilepsy 11 2.4 14 0.6 <0.001
Postindex; Antiepileptics 16 3.5 17 0.7 <0.001
*Dismissed: only before index, not after.
†Acquired: not before index, only after.
abnormal electroencephalograms were more common 
among LQTS patient when compared with their geno-neg-
ative relatives, though the abnormalities were not diag-
nostic for epilepsy.20 Also, a study found a higher preva-
lence of epilepsy among LQTS patients when compared 
with the lifetime prevalence in children.10 Our results 
support the idea that the relationship between the LQTS 
and epilepsy may extend beyond phenotypic mimicry.21 
However, in 74% of our LQTS patients with an epilepsy 
diagnosis prior to the LQTS index, the epilepsy diagnosis 
did not reappear in the registries after diagnosing LQTS. 
This may suggest that in at least some cases, the epilepsy 
diagnosis have been revised following the LQTS diag-
nosis. Epileptiform activity has been observed in patients 
with verified LQTS, but it remains uncertain whether 
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Table 3 Analysis of diabetes before and after long QT 
syndrome (LQTS) diagnosis
LQTS Controls
P valueN % N %
Anytime; Diabetes 17 3.7 42 1.8 0.011
Anytime; Antidiabetic drugs 24 5,2 45 1,9 <0.001
Anytime; Insulin 9 1.9 15 0,6 0.006
Preindex; Diabetes 10 2.2 28 1.2 0.108
Preindex; Antidiabetic 
drugs
21 4,5 39 1,7 <0.001
Preindex; Insulin 8 1,7 13 0,6 0.008
Postindex; Diabetes 12 2,6 26 1,1 0.013
Postindex; Antidiabetic 
drugs
22 4,8 43 1,9 <0.001
Postindex; Insulin 8 1,7 14 0,6 0.013
secondary phenomenon due to transient cerebral hypop-
erfusion or head traumas caused by LQTS arrhythmias or 
vasovagal syncope, frequently observed in LQTS patients. 
Despite these uncertainties, which are not easily distin-
guished in registry data, we found that epilepsy was signif-
icantly more prevalent among LQTS patients.
Hearing loss, which was the extracardiac manifestation 
first characterised in LQTS, was also found to be more 
prevalent among our LQTS patients compared with the 
control population. Hearing loss was initially linked to 
the LQTS subtype Jervell-Lange-Nielsen syndrome, which 
may be the main driver for the findings of increased 
risks in this study. However, it may be worth considering, 
that studies have determined an incidence of 1.6–6 per 
million (with a Danish population of 5.7 million) and 
that only 27% of patients with putative KCNQ1 mutations 
suffers from overt hearing loss due to reduced pene-
trance.22 Consequently, we would expect 2–9 cases of 
Jervell-Lange-Nielsen syndrome with hearing loss in the 
Danish population, compared with the 15 LQTS patients 
in this study with a diagnosis of hearing loss. As these 
crude estimates remain indicative at best, and due to the 
lack of data on LQTS subtype and genotypes, as well as 
the unknown accuracy of the hearing loss diagnosis in 
our registries, further observational studies are warranted 
to address these associations in detail.
Psychiatric comorbidities
In our cohort, LQTS patients had an increased risk of 
psychiatric disorder. A trend was found toward LQTS 
may have more mental disorders due to substance use 
and as LQTS patients may live in fear of life-threatening 
events,23 it could be hypothesised that this represent a 
subclinical proxy for anxiety and depression. Neverthe-
less, this finding is important as especially cocaine may 
elicit the arrhythmic phenotype of LQTS and therefore 
should be avoided.24 25
Our results show no association between LQTS and 
schizophrenia nor mental retardation, despite that studies 
on the molecular level have demonstrated a possible 
association between isoforms of the hERG channel (espe-
cially the KCNH2-3.1 isoform) and the development of 
schizophrenia and impaired cognition. However, this 
isoform is primarily expressed in cerebral neurons and 
only sparse in cardiac cells.11 26
Metabolic comorbidities
In our study cohort, we observed an increased prevalence 
of diabetes, as well as higher prescription rates of anti-
diabetic medication, among LQTS patients compared 
with the background population, which has not previ-
ously been reported in a real-life clinical LQTS popu-
lation. These analyses were decided on a priori, as the 
LQTS gene, KCNQ1, has previously been associated with 
type 2 diabetes in genome-wide association studies.27 28 
These observations led to clinical studies demonstrating 
increased insulin release and temporary insulin resist-
ance in LQTS patients with both KCNQ115 and KCNH2 
mutations,14 which might provide a possible explanation 
for our findings. Still, LQTS patients will inevitably have 
more blood test done compared with the background 
population—leading to a higher probability of being 
diagnosed with diabetes. However, in our cohort, 88% 
of the patients started antidiabetic treatment before the 
patients were diagnosed with LQTS, suggesting a limited 
bias.
In our data, less than three LQTS patients had a hypo-
glycaemia diagnosis, but as hypoglycaemic symptoms may 
often be misinterpreted as dizziness or mood changes, 
and only rarely arrhythmias, they may be undiagnosed 
in some cases. Still, this potential extracardiac manifes-
tation may be important to consider in future studies, as 
the hyperinsulinaemia studies14 15 raised concern about 
hypoglycaemia in LQTS patients. Considering additional 
interactions, a recent study by Poterucha et al suggested 
that beta-receptor blocking agents could cause hypogly-
caemia in children with LQTS.29 However, the effect of 
beta-receptor blocking agents has earlier been tested 
in healthy adults, showing no hypoglycaemic effect, 
suggesting that the hypoglycaemia in LQTS patients is 
independent of beta-blocker therapy.30
Limitations
This study was based on data from the well-characterised 
nationwide registries. Further, we specifically validated 
the LQTS diagnosis for the purpose of this study and 
found a high positive predictive value of 98% for the 
LQTS diagnostic code. Also, to minimise the risk of bias 
due to inclusion of acquired LQTS in our full cohort, 
patients were systematically excluded if diagnosed with 
acquired LQTS after index.
Still, due to the study’s retrospective design, we were 
only able to determine associations and not causality. 
Based on the available data, the LQTS patients could not 
be subgrouped based on genotype, the severity of disease 
or length of QT-interval. Also, only diagnoses given in a 
hospital setting (in-hospital and outpatient clinics) were 
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Special populations
epilepsy and diabetes, we also investigated use of antie-
pileptic drugs and antidiabetic drugs as a proxy for 
these comorbidities. However, minor comorbidities and 
complications managed in a primary care setting, such as 
mild depression and others, may have been missed.
Our findings could be biassed by the fact that LQTS 
over time may have more contacts with the health-
care system with a subsequent higher risk of additional 
diagnosis, compared with the background population. 
However, our subanalyses on diabetes showed that in 
most cases antidiabetic treatment was initiated before 
index and since only a few comorbidities were more 
frequent among LQTS patients, this does not seem to 
be a major issue. Nevertheless, the increased prevalence 
of comorbidities reflects the diagnostic odyssey many 
patients with LQTS go through before finally obtaining 
the LQTS diagnosis. Finally, as LQTS is a rare disease, our 
data are also limited by a low number of patients, and our 
results would preferably be tested in larger cohorts.
COnCLusIOn
Patients with LQTS had a significantly increased burden 
of diabetes, and neurological and psychiatric comorbid-
ities compared with an age and gender-matched back-
ground population. The increased burden of neurolog-
ical diagnoses was largely driven by an increased risk of 
epilepsy. However, after patients had been diagnosed 
with LQTS, the epilepsy diagnosis did not reappear in 
74% of the patients. This finding suggests that, at least in 
some cases, the epilepsy diagnosis may have been revised 
following the LQTS diagnosis. Although, we found 
that LQTS patients have a higher burden of psychiatric 
comorbidities, the difference could not be attributed to 
a specific subgroup of psychiatric diagnoses. Our data 
support that LQTS may be considered a multiorgan 
disease and suggest that patient care should be adjusted 
accordingly.
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